2025-06-16-Jefferies-邀请_高血压网络直播-美国东部时间今日上午10点_8页_249kb

Jefferies announced an equity research webcast on June 16, 2025, at 10:00 AM ET, focusing on the hypertension market, featuring biotech and medtech analysts. The discussion covers novel therapeutics and devices, reimbursement challenges, and payer perspectives. Key companies analyzed include Alnylam Pharmaceuticals (ALNY), AstraZeneca PLC (AZN), Boston Scientific Corp (BSX), Medtronic PLC (MDT), and Mineralys Therapeutics Inc (MLYS). Price targets and risks were provided: ALNY's $328 PT with risks of efficacy and competition; AZN's $74.42, risky due to R&D and generics; BSX's $122 PT under macro headwinds; MDT's $90 PT with regulatory risks; MLYS's HOLD rating with clinical and commercial risks. Overall, the report highlights investment ratings with Buy, Hold, and Underperform categories based on valuation analyses.